The regulatory registration enables Cellav to commercially market its product in the UK and represents an important step in the Company's broader strategy to establish a global presence in the fast-growing regenerative aesthetics and longevity markets.

The product has been successfully notified on the UK Cosmetic Product Notification (UKCP) portal. This UK registration complements Cellav's recent U.S. regulatory progress and expands the Company’s commercial footprint into one of Europe's leading medical aesthetics markets. With the UK market size estimated at approximately $900 million in 2026 and the European market exceeding $7.5 billion in 2025, we believe that the regulatory registration represents a significant step in Cellav's strategy to bring regenerative and cell-derived aesthetic products to a growing customer base that is seeking advanced, science-driven solutions.

The registered product, Regenativo+, a plant-derived treatment, is designed for professional aesthetic use and is based on Cellav's science-driven approach to regenerative aesthetics, leveraging advanced bioactive ingredients and formulations developed through Pluri's extensive expertise in cell biology and scalable manufacturing.

Cellav's aesthetic platform is part of Pluri's broader strategy to expand beyond traditional therapeutic applications and create new value-generating opportunities based on the Company's proprietary cell-expansion technologies and two decades of expertise in cell-derived products.